DOCSLIB.ORG

Brandon Marshall Has Shared Papers with You the Shared Folder 'Supervised Consumption Papers' Contains 80 Papers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brandon Marshall Has Shared Papers with You the Shared Folder 'Supervised Consumption Papers' Contains 80 Papers Brandon Marshall has shared papers with you The shared folder 'Supervised Consumption Papers' contains 80 papers. The Injection Support Team: a peer-driven program to address unsafe injecting in a Canadian setting Small W, Wood E, Tobin D, Rikley J, Lapushinsky D, Kerr T Subst. Use Misuse, 2012 — Journal Article View PDF Website ▶ Abstract Use of North America's rst medically supervised safer injecting facility among HIV-positive injection drug users Reddon H, Wood E, Tyndall M, Lai C, Hogg R, Montaner J, Kerr T AIDS Educ. Prev., 2011 — Journal Article View PDF Website ▶ Abstract Seeking refuge from violence in street-based drug scenes: women's experiences in North America's rst supervised injection facility Fairbairn N, Small W, Shannon K, Wood E, Kerr T Soc. Sci. Med., 2008 — Journal Article View PDF Website ▶ Abstract Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T BMC Public Health, 2008 — Journal Article View PDF Website ▶ Abstract Vancouver's supervised injection facility challenges Canada's drug laws Dooling K, Rachlis M CMAJ, 2010 — Journal Article View PDF Website ▶ Abstract The Canadian government's treatment of scientic process and evidence: inside the evaluation of North America's rst supervised injecting facility Wood E, Kerr T, Tyndall MW, Montaner JS Int. J. Drug Policy, 2008 — Journal Article View PDF Website ▶ Abstract Vancouver's INSITE service and other supervised injection sites: What has been learned from research? Health Canada Expert Advisory Committee Health Canada, 2010 — Book Website Recent incarceration linked to cutaneous injection-related infections among active injection drug users in a Canadian setting Milloy MJ, Wood E, Lloyd-Smith E, Grafstein E, Tyndall M, Montaner J, Kerr T J. Community Health, 2010 — Journal Article View PDF Website ▶ Abstract Tests support fentanyl contamination fears; Results from supervised injection site in Vancouver show 86 per cent of illegal drugs taken by users contained toxic synthetic opioid Woo A, Gray J The Globe and Mail, 2016 — News Article Website Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Sheps S, Montaner JS, Kerr T BMC Public Health, 2010 — Journal Article View PDF Website ▶ Abstract Characteristics of young illicit drug injectors who use North America's rst medically supervised safer injecting facility Stoltz JA, Wood E, Miller C, Small W, Li K, Tyndall M, Montaner J, Kerr T Addict. Res. Theory, 2007 — Journal Article Website ▶ Abstract Insite - Supervised Injection Site Vancouver Coastal Health 2010 — Website Website Self-reported changes in drug use behaviors and syringe disposal methods following the opening of a supervised injecting facility in Copenhagen, Denmark Kinnard EN, Howe CJ, Kerr T, Skjødt Hass V, Marshall BD Harm Reduct. J., 2014 — Journal Article View PDF Website ▶ Abstract Injection drug users' access to a supervised injection facility in Vancouver, Canada: the inuence of operating policies and local drug culture Small W, Shoveller J, Moore D, Tyndall M, Wood E, Kerr T Qual. Health Res., 2011 — Journal Article View PDF Website ▶ Abstract Condom use among injection drug users accessing a supervised injecting facility Marshall BD, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T Sex. Transm. Infect., 2009 — Journal Article View PDF Website ▶ Abstract Reduction in overdose mortality after the opening of North America's rst medically supervised safer injecting facility: a retrospective population-based study Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T Lancet, 2011 — Journal Article View PDF Website ▶ Abstract Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use Collins CL, Kerr T, Kuyper LM, Li K, Tyndall MW, Marsh DC, Montaner JS, Wood E J. Urban Health, 2005 — Journal Article View PDF Website ▶ Abstract Use of a medically supervised injection facility among street youth Hadland SE, DeBeck K, Kerr T, Nguyen P, Simo A, Montaner JS, Wood E J. Adolesc. Health, 2014 — Journal Article View PDF Website ▶ Abstract Injecting-related injury and disease among clients of a supervised injecting facility Salmon AM, Dwyer R, Jauncey M, van Beek I, Topp L, Maher L Drug Alcohol Depend., 2009 — Journal Article View PDF Website ▶ Abstract The Nordic countries and public drug-injection facilities Skretting A Drugs: Education, Prevention and Policy, 2006 — Journal Article Website ▶ Abstract ← Back Page 1 of 4 → Next © 2019 Paperpile LLC Features Terms of Service Brandon Marshall has shared papers with you The shared folder 'Supervised Consumption Papers' contains 80 papers. Prevalence and correlates of hepatitis C infection among users of North America's rst medically supervised safer injection facility Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, Tyndall MW Public Health, 2005 — Journal Article View PDF Website ▶ Abstract Injection drug use cessation and use of North America's rst medically supervised safer injecting facility DeBeck K, Kerr T, Bird L, Zhang R, Marsh D, Tyndall M, Montaner J, Wood E Drug Alcohol Depend., 2011 — Journal Article View PDF Website ▶ Abstract Summary of ndings from the evaluation of a pilot medically supervised safer injecting facility Wood E, Tyndall MW, Montaner JS, Kerr T CMAJ, 2006 — Journal Article View PDF Website ▶ Abstract Circumstances of rst injection among illicit drug users accessing a medically supervised safer injection facility Kerr T, Tyndall MW, Zhang R, Lai C, Montaner JS, Wood E Am. J. Public Health, 2007 — Journal Article View PDF Website ▶ Abstract Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ Int. J. Drug Policy, 2014 — Journal Article View PDF Website ▶ Abstract IDU perspectives on the design and operation of North America's rst medically supervised injection facility Small W, Ainsworth L, Wood E, Kerr T Subst. Use Misuse, 2011 — Journal Article View PDF Website ▶ Abstract The use of knowledge translation and legal proceedings to support evidence-based drug policy in Canada: opportunities and ongoing challenges Debeck K, Kerr T Open Med., 2010 — Journal Article View PDF Website ▶ Abstract Novel interventions to prevent HIV and HCV among persons who inject drugs Cofn PO, Rowe C, Santos GM Curr. HIV/AIDS Rep., 2015 — Journal Article View PDF Website ▶ Abstract Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility DeBeck K, Wood E, Zhang R, Tyndall M, Montaner J, Kerr T Subst. Abuse Treat. Prev. Policy, 2008 — Journal Article View PDF Website ▶ Abstract Supervised injection services: what has been demonstrated? A systematic literature review Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B Drug Alcohol Depend., 2014 — Journal Article View PDF Website ▶ Abstract Incarceration experiences in a cohort of active injection drug users Milloy MJ, Wood E, Small W, Tyndall M, Lai C, Montaner J, Kerr T Drug Alcohol Rev., 2008 — Journal Article View PDF Website ▶ Abstract Willingness to use drug checking within future supervised injection services among people who inject drugs in a mid-sized Canadian city Kennedy MC, Scheim A, Rachlis B, Mitra S, Bardwell G, Rourke S, Kerr T Drug Alcohol Depend., 2018 — Journal Article View PDF Website ▶ Abstract Employment among users of a medically supervised safer injection facility Richardson L, Wood E, Zhang R, Montaner J, Tyndall M, Kerr T Am. J. Drug Alcohol Abuse, 2008 — Journal Article View PDF Website ▶ Abstract Service uptake and characteristics of injection drug users utilizing North America's rst medically supervised safer injecting facility Wood E, Tyndall MW, Qui Z, Zhang R, Montaner JS, Kerr T Am. J. Public Health, 2006 — Journal Article View PDF Website ▶ Abstract Do supervised injecting facilities attract higher-risk injection drug users? Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JS, Kerr T Am. J. Prev. Med., 2005 — Journal Article View PDF Website ▶ Abstract Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benet analysis of a hypothetical supervised injection facility Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG Harm Reduct. J., 2017 — Journal Article View PDF Website ▶ Abstract Is Vancouver Canada's supervised injection facility cost-saving? Pinkerton SD Addiction, 2010 — Journal Article View PDF Website ▶ Abstract Assessing support for supervised injection services among community stakeholders in London, Canada Bardwell G, Scheim A, Mitra S, Kerr T Int. J. Drug Policy, 2017 — Journal Article View PDF Website ▶ Abstract Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it? McGowan CR, Harris M, Platt L, Hope V, Rhodes T Int. J. Drug Policy, 2018 — Journal Article View PDF Website ▶ Abstract Changes in public order after the opening of an overdose monitoring facility for people who inject drugs León C, Cardoso LJP, Johnston S, Mackin S, Bock B, Gaeta JM Int. J. Drug Policy, 2018 — Journal Article View PDF Website ▶ Abstract ← Back Page 2 of 4 → Next © 2019 Paperpile LLC Features Terms of Service Brandon Marshall has
Load more

Recommended publications
  • Overdose Prevention Centers
    Overdose Prevention Centers January 2019 Overview OPCs Improve Safety and Health Overdose prevention centers (OPCs) – also called Numerous evidence-based, peer-reviewed studiesiv safer consumption spaces (SCS), safer injection have proven the positive impacts of overdose facilities (SIFs), drug consumption rooms (DCRs), prevention centers, including: supervised drug consumption facilities (SCFs) or safer Increasing use of substance use disorder drug use services (SDUs) – are legally sanctioned treatment, especially among people who facilities designed to reduce the health and public distrust the treatment system and are order issues often associated with public injection. unlikely to seek treatment on their own; Reducing public disorder, reducing These facilities provide a space for people to public injecting, and increasing consume pre-obtained drugs in controlled settings, public safety; under the supervision of trained staff, and with access Attracting and retaining a population of to sterile injecting equipment. Participants can also people who inject drugs and are at a high receive health care, counseling, and referrals to health risk for infectious disease and overdose; and social services, including drug treatment. Reducing HIV and Hepatitis C risk behavior (i.e. syringe sharing, unsafe sex); There are approximately 120 OPCs currently Reducing the prevalence and harms of bacterial infections; operating in ten countries around the world (Australia, Successfully managing hundreds of Canada, Denmark, France, Germany, Luxembourg, overdoses and reducing drug-related the Netherlands, Norway, Spain and Switzerland) – overdose death rates; but none in the U.S.i In the past two years, Canada, Saving costs due to a reduction in and especially the city of Vancouver, has grown from disease, overdose deaths, and need two authorized sites to thirty, plus multiple smaller for emergency medical services; temporary sites set up to address the immediate need Providing safer injection education, in a community.
    [Show full text]
  • STATUS of HOUSE BUSINESS INDEX, 41St PARLIAMENT, 1St SESSION 1
    STATUS OF HOUSE BUSINESS INDEX, 41st PARLIAMENT, 1st SESSION 1 2call.ca Aboriginal peoples Government contracts C-10 Q-490 (Simms, Scott) M-81 (Davies, Libby) Meier, Matt M-82 (Davies, Libby) Q-490 (Simms, Scott) M-83 (Davies, Libby) Telephone systems and telephony M-202 (Angus, Charlie) Q-490 (Simms, Scott) M-402 (Bennett, Hon. Carolyn) 5 Wing. See Canadian Forces Base Goose Bay M-411 (Bennett, Hon. Carolyn) Q-43 (Bennett, Hon. Carolyn) 5 Wing Goose Bay. See Canadian Forces Base Goose Bay Q-46 (Bennett, Hon. Carolyn) 200-mile limit Q-224 (Duncan, Kirsty) Q-1296 (Cleary, Ryan) Q-233 (Toone, Philip) 444 Combat Support Squadron Q-234 (Toone, Philip) Military aircraft Q-300 (Goodale, Hon. Ralph) Q-652 (Garneau, Marc) Q-356 (Toone, Philip) Q-361 (Rae, Hon. Bob) Q-396 (Crowder, Jean) Q-402 (Fry, Hon. Hedy) Q-504 (Bennett, Hon. Carolyn) A Q-522 (Bevington, Dennis) Q-547 (Hsu, Ted) Q-677 (Toone, Philip) ABA. See Applied Behavioural Analysis Q-719 (Hsu, Ted) Abandoned oil wells. See Oil wells Q-797 (LeBlanc, Hon. Dominic) Abandoned rail lines. See Rail line abandonment Q-858 (Crowder, Jean) Abandoned railroads. See Rail line abandonment Q-859 (Crowder, Jean) Q-925 (Hughes, Carol) Abandoned railway lines. See Rail line abandonment Q-932 (Genest-Jourdain, Jonathan) Abandoned railways. See Rail line abandonment Q-938 (Genest-Jourdain, Jonathan) Abandoned vessels Q-939 (Genest-Jourdain, Jonathan) C-231 (Crowder, Jean) Q-980 (Boivin, Françoise) Abandonment of lines. See Rail line abandonment Q-1189 (Bennett, Hon. Carolyn) Q-1391 (Cotler, Hon. Irwin) Abandonment of rail lines.
    [Show full text]
  • Needle Sharing Among Intravenous Drug Abusers: National and International Perspectives
    Needle Sharing Among Intravenous Drug Abusers: National and International Perspectives U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Needle Sharing Among Intravenous Drug Abusers: National and International Perspectives Editors: Robert J. Battjes, D.S.W. Roy W. Pickens, Ph.D. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 80 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple University School of Medrcrne National Federation of Parents for Philadelphia. Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic Institute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE. Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.
    [Show full text]
  • Treatment of Alzheimer's Disease and Blood–Brain Barrier Drug Delivery
    pharmaceuticals Review Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery William M. Pardridge Department of Medicine, University of California, Los Angeles, CA 90024, USA; [email protected] Received: 24 October 2020; Accepted: 13 November 2020; Published: 16 November 2020 Abstract: Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has not developed BBB drug delivery technology, which would enable industry to invent new therapeutics for AD that actually penetrate into brain parenchyma from blood. In 2020, less than 1% of all AD drug development projects use a BBB drug delivery technology. The pathogenesis of AD involves chronic neuro-inflammation, the progressive deposition of insoluble amyloid-beta or tau aggregates, and neural degeneration. New drugs that both attack these multiple sites in AD, and that have been coupled with BBB drug delivery technology, can lead to new and effective treatments of this serious disorder. Keywords: blood–brain barrier; brain drug delivery; drug targeting; endothelium; Alzheimer’s disease; therapeutic antibodies; neurotrophins; TNF inhibitors 1. Introduction Alzheimer’s Disease (AD) afflicts over 50 million people world-wide, and this health burden costs over 1% of global GDP [1].
    [Show full text]
  • Supervised Injection Services Toolkit
    Supervised Injection Services Toolkit Toronto Drug Strategy June 2013 Supervised Injection Services Toolkit This report was prepared by the Toronto Drug Strategy's Supervised Injection Services Working Group whose members included the following: Gord Perks City Councillor and Chair, Toronto Drug Strategy Implementation Panel Raffi Balian Representative, Toronto Drug Users Union Zoe Dodd Representative, Toronto Drug Users Union Richard Elliott Executive Director, Canadian HIV/AIDS Legal Network Randy Franks Staff Inspector, Drug Squad, Toronto Police Service Diana Grimaldos Community member Dr. Curtis Handford Addictions Medicine, St. Michael's Hospital Shaun Hopkins Manager, The Works, Toronto Public Health Greg Khaymov Youth representative Dennis Long Executive Director, Breakaway Addiction Services Robert McKay Peer representative, Toronto Harm Reduction Task Force Lynn Anne Mulrooney Senior Policy Analyst, Registered Nurses' Association of Ontario Dr. Rita Shahin Associate Medical Officer of Health, Toronto Public Health Roslyn Shields Senior Policy Analyst, Centre for Addiction and Mental Health Please note: This report represents the best advice of the members of the Supervised Injection Services Working Group. It does not constitute formal endorsement by the organizations or groups they represent. Policy and administrative support was provided by the Toronto Drug Strategy Secretariat: Susan Shepherd, Manager Johanne DeCastro, Support Assistant Stephanie Venneri, Masters of Social Work Intern Thanks also for the assistance and contributions of the following: Camille Arkell, Dala Lana School of Public Health, University of Toronto Dr. Ahmed Bayoumi, St. Michael's Hospital and University of Toronto Chris Buchner, Vancouver Coastal Health Maxine Davis, Dr. Peter Centre, Vancouver Brent Granby, West End Residents Association Laura Hanson, Regent Park Community Health Centre Jann Houston, Toronto Public Health Wes Regan, Hastings Crosstown Business Improvement Association Tina Sahay, Toronto Public Health Dr.
    [Show full text]
  • Insite 2010 Cookbook
    Insite 2010 Cookbook Table of Contents 1. Powders and Crystals 1.1 Heroin p. 3 1.2 Cocaine p. 4 1.3 Methamphetamine p. 5 2. Rocks 2.1 Rock Cocaine p. 6 3. Tablets and Peelers 3.1 Dilaudid p. 7 3.2 Tablets (all others) p. 8 3.3 Peelers p. 9 4. Time Release Capsules 4.1 Small Time Release Capsules p. 10 4.2 Large Time Release Capsules p. 11 5. Patches 5.1 Fentanyl p. 12 6. Pastes 6.1 Tar Heroin, Opium p. 13 7. Liquids 7.1 Morphine p. 14 8. Approximate Analgesic Table 1: Drug Approximate Equivalent Dose p. 15 Equivalences 9. Additional Resources on Drug- References p. 16 Use Equipment, Disposal and Education Suggested Citation: Insite. Insite 2010 Cookbook. 2010 (updated 2018). 16 p. 2 1. Powders and Crystals 1.1: Heroin: (Down, Smack, H, Dope, Horse, China White, Apple Juice, Junk) Distinctive Feature: Dissolves in water with heat. Notes: Some heroin comes in a rock form and needs to be crushed into a powder. Pour powder into cooker. Heat lightly to edge of boil (when first bubbles of boiling appear). Sometimes you need to stir with syringe plunger to help the powder dissolve. Repeat heating and stirring process until powder dissolves. There may be a wash left behind. You can use a Sterifilt on this. Supplies: Cooker Syringe Sterile water Filter Tourniquet Fire (matches, candle, lighter) Alcohol wipes Gauze Technique: 1. Wash Hands 2. Remove cooker from package, attach plastic handle cover 3. Put drug into cooker (If the heroin is in a hardened rock form it needs to be crushed) 4.
    [Show full text]
  • Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010 Xizhong Cui,1 Leisha D
    RESEARCH Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010 Xizhong Cui,1 Leisha D. Nolen,1 Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, Peter Q. Eichacker This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 175. Release date: December 15, 2016; Expiration date: December 15, 2017 Learning Objectives Upon completion of this activity, participants will be able to: 1. Assess recommendations for the management of systemic anthrax and the use of anthrax immune globulin intravenous (AIG-IV) 2. Distinguish variables associated with the application of AIG-IV in the current study 3.
    [Show full text]
  • Supervised Injection Services: What Has Been Demonstrated?
    Drug and Alcohol Dependence 145 (2014) 48–68 Contents lists available at ScienceDirect Drug and Alcohol Dependence j ournal homepage: www.elsevier.com/locate/drugalcdep Review Supervised injection services: What has been demonstrated? ଝ A systematic literature review a,b,∗ c,d e a,b Chloé Potier , Vincent Laprévote , Franc¸ oise Dubois-Arber , Olivier Cottencin , a,b Benjamin Rolland a Department of Addiction Medicine, CHRU de Lille, Univ Lille Nord de France, F-59037 Lille, France b University of Lille 2, Faculty of Medicine, F-59045 Lille, France c CHU Nancy, Maison des Addictions, Nancy F-54000, France d CHU Nancy, Centre d’Investigation Clinique CIC-INSERM 9501, Nancy F-54000, France e Institute of Social and Preventive Medicine, University Hospital Center and University of Lausanne, Chemin de la Corniche 10, 1010 Lausanne, Switzerland a r t i c l e i n f o a b s t r a c t Article history: Background: Supervised injection services (SISs) have been developed to promote safer drug injection Received 18 May 2014 practices, enhance health-related behaviors among people who inject drugs (PWID), and connect PWID Received in revised form 14 October 2014 with external health and social services. Nevertheless, SISs have also been accused of fostering drug use Accepted 14 October 2014 and drug trafficking. Available online 23 October 2014 Aims: To systematically collect and synthesize the currently available evidence regarding SIS-induced benefits and harm. Keywords: Methods: A systematic review was performed via the PubMed, Web of Science, and ScienceDirect Supervised injection service databases using the keyword algorithm [(“SUPERVISED” OR “SAFER”) AND (“INJECTION” OR “INJECT- Safer injection facility ING” OR “SHOOTING” OR “CONSUMPTION”) AND (“FACILITY” OR “FACILITIES” OR “ROOM” OR “GALLERY” Supervised injecting center Drug consumption room OR “CENTRE” OR “SITE”)].
    [Show full text]
  • Prescription Stimulants
    Prescription Stimulants What are prescription stimulants? Prescription stimulants are medicines generally used to treat attention-deficit hyperactivity disorder (ADHD) and narcolepsy— uncontrollable episodes of deep sleep. They increase alertness, attention, and energy. What are common prescription stimulants? • dextroamphetamine (Dexedrine®) • dextroamphetamine/amphetamine combination product (Adderall®) • methylphenidate (Ritalin®, Concerta®). Photo by ©iStock.com/ognianm Popular slang terms for prescription stimulants include Speed, Uppers, and Vitamin R. How do people use and misuse prescription stimulants? Most prescription stimulants come in tablet, capsule, or liquid form, which a person takes by mouth. Misuse of a prescription stimulant means: Do Prescription Stimulants Make You • taking medicine in a way or dose Smarter? other than prescribed Some people take prescription stimulants to • taking someone else’s medicine try to improve mental performance. Teens • taking medicine only for the effect it and college students sometimes misuse causes—to get high them to try to get better grades, and older adults misuse them to try to improve their When misusing a prescription stimulant, memory. Taking prescription stimulants for people can swallow the medicine in its reasons other than treating ADHD or normal form. Alternatively, they can crush narcolepsy could lead to harmful health tablets or open the capsules, dissolve the powder in water, and inject the liquid into a effects, such as addiction, heart problems, vein. Some can also snort or smoke the or psychosis. powder. Prescription Stimulants • June 2018 • Page 1 How do prescription stimulants affect the brain and body? Prescription stimulants increase the activity of the brain chemicals dopamine and norepinephrine. Dopamine is involved in the reinforcement of rewarding behaviors.
    [Show full text]
  • Analysis CMAJ
    van-rachlis_Layout 1 01/09/10 10:39 AM Page 1440 Analysis CMAJ Vancouver’s supervised injection facility challenges Canada’s drug laws Kathleen Dooling MD MPH, Michael Rachlis MD LLD Previously published at www.cmaj.ca arm reduction for injection drug users started with Key points community-based programs to provide clean nee- dles and has grown to include supervised injection • Research suggests that medically supervised injection of illicit H drugs reduces needle-sharing and deaths from overdose and facilities. Such services have existed for several years in improves public order and uptake of addiction treatment. Australia and Europe.1 In 2003, North America’s first sanc- • Two courts in the province of British Columbia have tioned supervised injection facility, Insite, was opened in the upheld the constitutional legality of supervised injection at Downtown Eastside of Vancouver, British Columbia. To Vancouver’s Insite facility. permit the facility to open, the then Canadian Liberal gov- • The federal government remains politically opposed to Insite ernment exempted Insite from some provisions of the Con- and is appealing the case to the Supreme Court of Canada. trolled Drugs and Substances Act relating to trafficking. In 2006, a Conservative government was elected. It elimi- nated harm reduction as a pillar of Canada’s antidrug policy and Ninety percent of the deaths were associated with heroin, two- began to threaten Insite with suspension of the federal exemp- thirds of the time in combination with alcohol and other drugs. tion. In this article, we examine the role of scientific evidence By 1993, use of illicit drugs was the leading cause of death in and how a clash of values about harm reduction eventually led to British Columbia among men and women aged 15–44 years.6 two courts in the province of British Columbia to decide in This epidemic of overdose-related deaths prompted the favour of Insite and possibly other controversial forms of harm creation of a task force led by the province’s then chief coro- reduction, such as supervised inhalation.
    [Show full text]
  • Bill C-2 an Act to Amend the Controlled Drugs and Substances Act (Respect for Communities Act)
    Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act) Canadian Medical Association Submission to the House of Commons Standing Committee on Public Safety and National Security October 28, 2014 The Canadian Medical Association (CMA) is the national voice of Canadian physicians. Founded in 1867, CMA’s mission is to help physicians care for patients. On behalf of its more than 82,000 members and the Canadian public, CMA performs a wide variety of functions. Key functions include advocating for health promotion and disease prevention policies and strategies, advocating for access to quality health care, facilitating change within the medical profession, and providing leadership and guidance to physicians to help them influence, manage and adapt to changes in health care delivery. The CMA is a voluntary professional organization representing the majority of Canada’s physicians and comprising 12 provincial and territorial divisions and 51 national medical organizations. 1 The Canadian Medical Association (CMA) provides this brief for consideration as part of House of Commons Standing Committee on Public Safety and National Security’s study of Bill C-2, An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act).1 Prior to a discussion on CMA’s position regarding the substance of Bill C-2, the CMA firstly recommends that legislation pertaining to harm reduction services requires study by parliamentary committees responsible for health or social matters in addition to public safety. Bill C-2 (formerly Bill C-65) is subsequent to the 2011 unanimous ruling of the Supreme Court of Canada2 that recognized the significant evidence on the benefits of Insite, Vancouver’s supervised injection site.
    [Show full text]
  • Problematic Substance Use in Ottawa Technical Report
    Problematic Substance Use in Ottawa Technical Report June 2016 REVISED pursuant to Motion 10/05, adopted by the Ottawa Board of Health on June 20, 2016 Table of Contents Acknowledgements .................................................................................................. 1 Introduction ............................................................................................................ 2 Executive Summary ................................................................................................. 3 Summary of Findings ............................................................................................... 4 Prevalence of problematic substance use .................................................................... 6 Drug-related morbidity ............................................................................................. 9 Emergency room visits due to drug overdose ........................................................... 9 Emergency room visits due to drug-related mental and behavioural conditions ............ 11 Drug-related mortality.............................................................................................14 Injection drug use ..................................................................................................20 Location of individuals who use drugs and of drug use................................................. 24 Paramedic responses to drug overdose in Ottawa .................................................... 24 OPH Site Needle and Syringe Program service
    [Show full text]